4.7 Article

Development of an ionic liquid-based dispersive liquid-liquid microextraction method for the determination of nifurtimox and benznidazole in human plasma

期刊

TALANTA
卷 107, 期 -, 页码 95-102

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.talanta.2012.12.050

关键词

Benznidazole; Nifurtimox; Antichagasic drugs; Dispersive liquid-liquid microextraction; Liquid chromatography; Ionic liquids

资金

  1. Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)
  2. Agencia Nacional de Promocion Cientifica y Tecnica (ANPCYT)
  3. Fundacion Bunge Born
  4. Programa Salud Investiga (Ministerio de Salud de la Republica Argentina)
  5. Facultad de Ciencias Exactas (UNLP)
  6. Comision de Investigaciones Cientificas de la Provincia de Buenos Aires (CIC-PBA)

向作者/读者索取更多资源

Dispersive ionic liquid-liquid microextraction combined with liquid chromatography and UV detection was used for the determination of two antichagasic drugs in human plasma: nifurtimox and benznidazole. The effects of experimental parameters on extraction efficiency-the type and volume of ionic liquid and disperser solvent, pH, nature and concentration of salt, and the time for centrifugation and extraction-were investigated and optimized. Matrix effects were detected and thus the standard addition method was used for quantification. This microextraction procedure yielded significant improvements over those previously reported in the literature and has several advantages, including high inter-day reproducibility (relative standard deviation=1.02% and 3.66% for nifurtimox and benznidazole, respectively), extremely low detection limits (15.7 ng mL(-1) and 26.5 ng mL(-1) for nifurtimox and benznidazole, respectively), and minimal amounts of sample and extraction solvent required. Recoveries were high (98.0% and 79.8% for nifurtimox and benznidazole, respectively). The proposed methodology offers the advantage of highly satisfactory performance in addition to being inexpensive, simple, and fast in the extraction and preconcentration of these antichagasic drugs from human-plasma samples, with these characteristics being consistent with the practicability requirements in current clinical research or within the context of therapeutic monitoring. (C) 2013 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据